Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,525,389,316.30, a decrease of 36.51% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 440,335,904.83, down 47.91% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 392,137,823.14, a decline of 46.01% compared to the previous year[4] - The net cash flow from operating activities was CNY 793,904,475.78, representing a decrease of 40.70% year-on-year[4] - Basic earnings per share were CNY 0.48, down 47.83% from CNY 0.92 in the same period last year[4] - The company's net profit for Q1 2025 was RMB 419,297,717.76, compared to RMB 808,269,636.78 in Q1 2024, reflecting a decline of 48.2%[19] - The total profit for Q1 2025 was CNY 514.67 million, down 48.0% from CNY 989.79 million in Q1 2024[21] Revenue and Costs - The total operating revenue for Q1 2025 was RMB 1,525,389,316.30, a decrease of 36.4% compared to RMB 2,402,545,954.32 in Q1 2024[19] - The total operating costs for Q1 2025 were RMB 1,106,091,598.54, down 30.6% from RMB 1,594,276,317.54 in Q1 2024[19] - The gross profit margin for Q1 2025 was approximately 27.5%, compared to 37.0% in Q1 2024[19] - The decline in revenue and profit was primarily due to reduced sales of major products and an increase in cost expense ratio[7] Assets and Liabilities - Total assets at the end of the reporting period were CNY 18,333,497,578.36, a decrease of 0.68% from the end of the previous year[5] - The total assets as of March 31, 2025, were RMB 18,333,497,578.36, a slight decrease from RMB 18,459,493,906.46 at the end of 2024[18] - The total liabilities decreased to RMB 3,166,200,048.41 as of March 31, 2025, from RMB 3,733,067,567.74 at the end of 2024, indicating a reduction of 15.2%[17] Shareholder Equity - Shareholders' equity attributable to shareholders was CNY 15,141,767,178.40, an increase of 2.99% compared to the end of the previous year[5] - The weighted average return on equity decreased by 3.19 percentage points to 2.95%[4] Cash Flow - The cash and cash equivalents increased to RMB 7,415,120,901.39 as of March 31, 2025, up from RMB 6,669,362,743.71 at the end of 2024, representing a growth of 11.2%[15] - The cash inflow from investment activities was CNY 917.85 million, significantly lower than CNY 2.12 billion in Q1 2024[24] - The company reported a net cash outflow from investing activities of CNY 9.20 million, contrasting with a net inflow of CNY 1.66 billion in Q1 2024[24] - The company reported a cash outflow from financing activities of CNY 322.58 million, compared to CNY 15.63 million in Q1 2024[24] Share Repurchase - The company has repurchased a total of 220,500 shares, accounting for 0.02% of the total share capital, with a total expenditure of RMB 6,099,831 as of March 31, 2025[13] - The company plans to continue share repurchase activities within the approved budget of RMB 2,500,000 to RMB 5,000,000, with a maximum repurchase price of RMB 48 per share[13] Expenses - The company reported a significant reduction in sales expenses, which were RMB 557,671,736.88 in Q1 2025, down from RMB 989,645,386.93 in Q1 2024, a decrease of 43.7%[19] - The company incurred credit impairment losses of CNY 37.36 million in Q1 2025, compared to CNY 41.48 million in Q1 2024[20]

Financial Performance - The company's operating revenue for 2024 was CNY 8,016,894,756.63, a decrease of 16.96% compared to CNY 9,654,537,192.67 in 2023 [24]. - Net profit attributable to shareholders for 2024 was CNY 2,531,554,060.02, down 10.32% from CNY 2,822,781,164.62 in 2023 [24]. - The net cash flow from operating activities decreased by 37.17% to CNY 2,176,437,015.78 in 2024, primarily due to reduced sales recovery [25]. - Basic earnings per share for 2024 were CNY 2.76, a decline of 10.39% from CNY 3.08 in 2023 [25]. - The weighted average return on equity decreased to 18.18% in 2024, down 4.81 percentage points from 22.99% in 2023 [25]. - The total revenue for the company was CNY 7,996,512,403.91, a decrease of 17.03% compared to the previous year [64]. - The gross margin for the main business was 79.34%, down by 2.29 percentage points year-on-year [64]. - The revenue from the pharmaceutical commercial segment accounted for 4.22% of the main business income [51]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants [5]. - The board of directors and supervisory board members have all attended the board meeting, ensuring the report's authenticity and completeness [4]. - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties [8]. - There are no violations of decision-making procedures regarding external guarantees [8]. - The company has not faced any issues with a majority of directors being unable to guarantee the authenticity of the annual report [8]. - The company has implemented strict information disclosure practices, ensuring timely and accurate information is available to all shareholders [128]. - The company has established a robust governance framework in line with regulatory requirements [128]. Research and Development - The company made progress in R&D, entering one Phase III clinical project and completing three bioequivalence studies for generic drugs [35]. - The company submitted 11 new invention patent applications in China and 1 PCT international patent application, receiving 3 Chinese invention patents and 1 European patent authorization [35]. - The company is focused on digital transformation, enhancing its IT resources and integrating business processes with financial systems to improve efficiency [38]. - The company is committed to talent development, focusing on attracting innovative talent and enhancing organizational efficiency [36]. - The company is focusing on the development of small molecule innovative drugs and modernization of traditional Chinese medicine, with a structured R&D decision-making system to identify high-value targets [116]. - The company has established specific criteria for capitalizing research and development expenditures, ensuring that only qualifying expenses are recognized as intangible assets [94]. Market and Product Development - The company plans to continue its market expansion and product development strategies to enhance future performance [33]. - The company introduced 4 product introduction or cooperation agreements, including new drugs in respiratory, pain, and ENT fields, enhancing its treatment pipeline [38]. - The company’s products, including pediatric medications, were included in the national medical insurance directory, increasing the total number of insured products to 40 [40]. - The company is actively optimizing its marketing operations and enhancing the capabilities of its market management team [36]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market [134]. Environmental and Social Responsibility - The company has committed to avoiding any future competition with its controlling shareholders and related parties, ensuring that it will not engage in similar business activities post-injection of Jichuan Pharmaceutical [189]. - The company has established an emergency response plan for environmental incidents, which was revised in July 2024 and filed with the relevant authorities [177]. - The company has implemented continuous improvements and refinements to its internal control systems based on industry characteristics and operational realities [163]. - The company has engaged third-party monitoring for its pollution discharge, ensuring adherence to environmental standards [170]. - The company has invested approximately 33.09 million yuan in environmental protection during the reporting period [165]. Governance and Management - The company has established a performance evaluation mechanism for senior management, linking their compensation to the achievement of annual business goals [162]. - The company has a structured approach to determining remuneration based on performance evaluation and departmental feedback [137]. - The company has maintained complete independence from its controlling shareholders in terms of assets, personnel, finance, institutions, and business operations [128]. - The company plans to propose a 2024 employee stock ownership plan at the upcoming shareholder meeting [130]. - The current management team includes experienced professionals with extensive backgrounds in the pharmaceutical industry, enhancing strategic decision-making capabilities [134].

湖北济川药业股份有限公司 根据证监会《上市公司独立董事管理办法》、上海证券交易所《股票上市规 则》《上市公司自律监管指引第 1 号--规范运作》等要求，湖北济川药业股份有 限公司（以下简称"公司"）董事会，就公司在任独立董事姚宏、卢超军、杨玉 海的独立性情况进行评估并出具如下专项意见： 董事会关于独立董事独立性情况的专项意见 湖北济川药业股份有限公司 董事会 2025 年 4 月 25 日 经核查独立董事姚宏、卢超军、杨玉海的任职经历以及签署的相关自查文件， 上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公司担 任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独 立客观判断的关系，不存在影响独立董事独立性的情况，公司独立董事符合《上 市公司独立董事管理办法》《上海证券交易所上市公司自律监管指引第 1 号-- 规范运作》中对独立董事独立性的相关要求。 ...

证券代码： 600566 证券简称： 济川药业 公告编号：2025-018 湖北济川药业股份有限公司 关于公司 2024 年募集资金存放与 实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》（证 监会公告〔2022〕15 号）、《上海证券交易所上市公司自律监管指引第 1 号——规范运作》以及《上海证券交易所上市公司自律监 管指南第 1 号——公告格式》的相关规定，湖北济川药业股份有限公司（以下简称"公司"、"本公司"或"济川药业"）就 2024 年度募集资金存放与使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 2020 年 7 月 15 日，经中国证券监督管理委员会证监许可（2020）1442 号文核准，湖北济川药业股份有限公司非公开发行人民 1 币普通股 73,329,853 股，发行价格为每股 19.16 元，募集资金总额人民币 1,404,999, ...

华泰联合证券有限责任公司关于湖北济川药业股份有限公司 2024年度募集资金存放与使用情况的专项核查报告 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作为 湖北济川药业股份有限公司（以下简称"济川药业"、"上市公司"或"公司"）2020 年非公开发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》、《上 海证券交易所股票上市规则》、《上市公司监管指引第2号——上市公司募集资 金管理和使用的监管要求》和《上海证券交易所上市公司自律监管指引第1号— —规范运作》等有关规定，对济川药业在2024年度募集资金存放与实际使用情况 进行了核查，核查情况如下： 一、募集资金的基本情况 经中国证券监督管理委员会证监许可[2020]1442号文核准，公司面向发行对 象非公开发行人民币普通股73,329,853股，发行价格19.16元/股，募集资金总额人 民 币 1,404,999,983.48 元，扣除发行有关费用后募集资金净额为人民币 1,383,772,031.38元。资金于2020年9月30日全部到位，已经立信会计师事务所（特 殊普通合伙）以信会师报字[2020]第ZA15713号验资报告验证。 ...

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-019 湖北济川药业股份有限公司 本公司董事会及全体成员保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖北济川药业股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开 第十届董事会第十四次会议、第十届监事会第十四次会议，审议通过了《关于部 分募投项目延期的议案》，同意公司在对募投项目实施主体、募集资金投资用途 及投资规模均不发生变更的情况下，结合当前募投项目的实施进度、实际建设情 况，将"数字化经营管理平台建设项目" 的完工时间延期至 2027 年 12 月。本 次部分募投项目延期事项无需提交股东大会审议。现将具体情况公告如下： 一、 募集资金及募投项目基本情况 （一）募集资金基本情况 关于部分募投项目延期的公告 2020 年 7 月 15 日，经中国证券监督管理委员会（以下简称"中国证监会） 证监许可（2020）1442 号文核准，湖北济川药业股份有限公司（以下简称"济 川药业"、"公司"）非公开发行人民币普通股 73,329,853 股，发行价格为每股 1 ...

湖北济川药业股份有限公司 募集资金年度存放与使用情况 鉴证报告 二〇二四年度 关于湖北济川药业股份有限公司 2024年度募集资金存放与使用情况专项报告的 鉴证报告 我们接受委托，对后附的湖北济川药业股份有限公司（以下简称 "公司"、 "本公司"或"济川药业"） 2024年度募集资金存放与使 用情况专项报告（以下简称"募集资金专项报告"）执行了合理保证 的鉴证业务。 一、董事会的责任 济川药业董事会的责任是按照中国证券监督管理委员会《上市公 司监管指引第2号——上市公司募集资金管理和使用的监管要求 （2022年修订）》（证监会公告〔2022〕15号）、《上海证券交易所 上市公司自律监管指引第1号——规范运作》以及《上海证券交易所 上市公司自律监管指南第1号——公告格式》的相关规定编制募集资 金专项报告。这种责任包括设计、执行和维护与募集资金专项报告编 制相关的内部控制，确保募集资金专项报告真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏。 鉴证报告第 1 页 信会师报字[2025 ]第ZA12160号 湖北济川药业股份有限公司全体股东： 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对募集资金 ...

2024 年度，公司共召开了 6 次监事会。具体情况如下： （一）2024 年 4 月 3 日召开了第十届监事会第七次会议，会议审议通过 了《关于全资子公司利用闲置自有资金进行现金管理的议案》。 （二）2024 年 4 月 9 日召开了第十届监事会第八次会议，会议审议通过 了《关于公司 2023 年度报告全文及摘要的议案》《关于公司 2023 年度监事会 工作报告的议案》《关于公司 2023 年度财务决算报告的议案》《关于公司 2023 年度利润分配方案的议案》《关于公司 2024 年度监事薪酬方案的议案》《关于公 司 2024 年员工持股计划（草案）及其摘要的议案》《关于公司 2024 年员工持 股计划管理办法的议案》《关于公司 2023 年度内部控制评价报告及内部控制审 计报告的议案》《关于公司 2023 年度募集资金存放与实际使用情况的专项报告 的议案》《关于部分募投项目变更的议案》《关于公司续聘立信会计师事务所（特 殊普通合伙）为 2024 年度审计机构的议案》《关于 2024 年度向银行等金融机 构申请综合授信额度的议案》 （三）2024 年 4 月 15 日召开了第十届监事会第九次会议，会议审议通 ...

湖北济川药业股份有限公司 2024 年度审计委员会履职情况报告 湖北济川药业股份有限公司（以下简称"公司"）董事会审计委员会根据中国证券监督 管理委员会、上海证券交易所的相关法律法规及《公司章程》、《董事会审计委员会工作细 则》等规定，在 2024 年度本着勤勉尽责的原则，积极开展工作，认真履行了职责。现对公 司董事会审计委员会 2024 年度的履职情况汇报如下： 一、 董事会审计委员会基本情况 公司第十届董事会审计委员会由 3 名委员组成，现任审计委员会委员分别为独立董事 杨玉海先生、独立董事姚宏先生以及董事黄曲荣先生，其中杨玉海先生担任召集人。 二、 董事会审计委员会会议召开情况 2024 年度，公司第十届董事会审计委员会共召开了 4 次会议，全体委员均亲自出席了 会议。 （一）2024 年 3 月 29 日，公司审计委员会 2024 年第一次会议召开并通过了《关于全 资子公司利用闲置自有资金进行现金管理的议案》《关于公司 2023 年度报告全文及摘要的 议案》《关于公司 2023 年度财务决算报告的议案》《关于公司 2023 年度利润分配预案的议 案》《关于公司 2023 年度审计委员会履职情况报告的议 ...